Search results for "tea"

showing 10 items of 7074 documents

Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C.

2014

Background & Aims: In Chronic Hepatitis C (CHC), the influence of steatosis on liver stiffness measurement (LSM) is still debated. We assessed the impact of steatosis and its ultrasonographical sign – bright liver echo pattern (BLEP) – on LSM values and on transient elastography (TE) accuracy for the diagnosis of liver fibrosis, in a cohort of consecutive patients with Genotype 1 (G1) CHC. Methods: Patients (n = 618) were assessed by clinical, ultrasonographic and histological (Scheuer score) features. TE was performed using the M probe. Results: Male gender (p = 0.04), steatosis as continuous variable (p <0.001), severity of necroinflammation (p = 0.02) and stage of fibrosis (p <0.001) wer…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisGenotypeBiopsyComorbidityHepacivirusSettore MED/08 - Anatomia PatologicaGastroenterologySensitivity and SpecificitySeverity of Illness IndexCohort StudiesFibrosisInternal medicineUltrasoundmedicineHumansNon-invasiveEvaluationAgedRetrospective StudiesUltrasonographySettore MED/12 - GastroenterologiaCirrhosiHepatologymedicine.diagnostic_testbusiness.industryFatty liverHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseElasticityFatty LiverLiverLiver biopsyCohortFibroscan®Cirrhosis; Evaluation; Fibroscan®; Non-invasive; UltrasoundFemaleSteatosisbusinessTransient elastographyJournal of hepatology
researchProduct

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the ev…

2013

Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity. The aim of this study was to determine whether the use of the SAF score and FLIP algorithm can decrease interobserver variations among pathologists. In a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according t…

AdultLiver CirrhosisMalemedicine.medical_specialtyConcordanceBiopsySettore MED/08 - Anatomia PatologicaSeverity of Illness IndexFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineSAF steatosis activity fibrosis.Nonalcoholic fatty liver diseaseBiopsyNAS nonalcoholic steatohepatitis activity scoremedicineHumansAgedObserver VariationHepatologymedicine.diagnostic_testbusiness.industryFatty liverGold standard (test)HepatologyMiddle Agedmedicine.diseaseFatty LiverLiverNASH nonalcoholic steatohepatitiDisease ProgressionFemaleNAFLD nonalcoholic fatty liver diseaseSteatosisbusinessAlgorithmAlgorithmsHepatology (Baltimore, Md.)
researchProduct

Evaluating the association of serum ferritin and hepatic iron with disease severity in non‐alcoholic fatty liver disease

2019

Background & Aims Hyperferritinemia, with or without increased hepatic iron, represents a common finding in non‐alcoholic fatty liver disease (NAFLD). However, it is unclear whether it reflects hepatic inflammation or true iron‐overload and, in case the latter is confirmed, whether this influences disease progression. We therefore explored the association between serum ferritin, degree and pattern of hepatic iron deposition and liver disease severity in patients with NAFLD. Methods We selected 468 patients with biopsy‐proven NAFLD from 2 European centres. Iron, hepatic and metabolic parameters were collected at the time of liver biopsy. Iron deposits in hepatocytes and reticuloendothelial c…

AdultLiver CirrhosisMalemedicine.medical_specialtyIron OverloadBiopsyGastroenterologyhistology03 medical and health sciencesLiver diseaseiron0302 clinical medicineFibrosisInternal medicinemedicineHumansRetrospective StudiesMetabolic SyndromeHepatologymedicine.diagnostic_testbiologybusiness.industryferritinFatty livernon-alcoholic fatty liver diseaseMononuclear phagocyte systemMiddle Agedmedicine.diseaseFerritinLogistic ModelsLiver030220 oncology & carcinogenesisLiver biopsyFerritinsDisease Progressionbiology.proteinFemale030211 gastroenterology & hepatologyAlcoholic fatty liverferritin; histology; iron; non-alcoholic fatty liver diseaseSteatohepatitisbusinessLiver International
researchProduct

Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease W…

2020

HEPAmet Registry.

AdultLiver CirrhosisMalemedicine.medical_specialtySteatosis[SDV]Life Sciences [q-bio]BiopsyLikelihood ratios in diagnostic testingGastroenterologySeverity of Illness IndexDecision Support Techniques03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePositive predicative valueInternal medicineNonalcoholic fatty liver diseaseHOMAMedicineHumansComputingMilieux_MISCELLANEOUSAged2. Zero hungerNASH FIBROSISHepatologymedicine.diagnostic_testReceiver operating characteristicbusiness.industryPrognostic FactorGastroenterologyOdds ratioMiddle Agedmedicine.diseasePrognosis3. Good healthCross-Sectional StudiesDiagnostic ToolCirrhosisLiver030220 oncology & carcinogenesisLiver biopsyDiagnostic odds ratio030211 gastroenterology & hepatologyFemalebusinessClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Histological Features of Cerebellar Neuropathology in Patients With Alcoholic and Nonalcoholic Steatohepatitis

2018

Alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH) affect 29 million people in the European Union. Patients with ASH and NASH may exhibit cognitive impairment, reducing their quality of life. Steatohepatitis induces cerebral alterations. It is not known if histological analysis could allow distinguishing ASH, NASH, and/or cirrhosis neuropathology and other entities. The aim of this work was to analyze a set of histopathological features characterizing the brain lesions due to ASH, NASH, and cirrhosis. We performed a histological study using hematoxylin and eosin staining and immunohistochemical techniques in cerebellum of 31 subjects who died with healthy liver (n = 6),…

AdultMale0301 basic medicinePathologymedicine.medical_specialtyAlcoholic liver diseaseCerebellumCell CountNeuropathologyPathology and Forensic Medicine03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineNon-alcoholic Fatty Liver DiseaseCerebellumHumansMedicinemedia_common.cataloged_instanceEuropean unionAgedmedia_commonNeuronsAnalysis of Variancebusiness.industryCalcium-Binding ProteinsMicrofilament ProteinsFatty liverGeneral MedicineMiddle Agedmedicine.diseaseDNA-Binding Proteins030104 developmental biologymedicine.anatomical_structureNeurologyFemaleCerebellar atrophyAlcoholic fatty liverNeurology (clinical)AtrophySteatohepatitisbusinessNeuroglia030217 neurology & neurosurgeryFatty Liver AlcoholicJournal of Neuropathology &amp; Experimental Neurology
researchProduct

Internal exposure of firefighting instructors to polycyclic aromatic hydrocarbons (PAH) during live fire training

2019

Firefighting instructors in live fire training are inevitably exposed to emissions containing, carcinogenic PAH. The study investigated PAH uptake in a group of firefighting instructors during short-term exposure in live fire training by urinary biomonitoring. Six firefighting instructors (non-smokers) completed five 2 h-training sessions each in a carbonaceous-fired simulation unit using self-containing breathing apparatuses (SCBA). Complying with a minimum time interval of six days between the individual training sessions, the participants provided urine samples before and immediately after, as well as 1, 3, 6, 9, 11, and 18 h after each training session. Samples were analyzed for 10 mono…

AdultMale0301 basic medicineSkin AbsorptionMetaboliteeducationPoison controlFirefightingAir Pollutants OccupationalUrineToxicologyFiresExcretion03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAnimal scienceOccupational ExposureBiomonitoringHumansPolycyclic Aromatic HydrocarbonsRespiratory Protective DevicesSkinChemistryTeachingGeneral MedicinePhenanthrene030104 developmental biologyFirefightersPyrene030217 neurology & neurosurgeryEnvironmental MonitoringToxicology Letters
researchProduct

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage

2016

The patatin-like phosholipase domain-containing 3 (PNPLA3) rs738409 polymorphism (I148M) is a major determinant of hepatic fat and predisposes to the full spectrum of liver damage in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate whether additional PNPLA3 coding variants contribute to NAFLD susceptibility, first in individuals with contrasting phenotypes (with early-onset NAFLD vs. very low aminotransferases) and then in a large validation cohort. Rare PNPLA3 variants were not detected by sequencing coding regions and intron-exon boundaries either in 142 patients with early-onset NAFLD nor in 100 healthy individuals with alanine aminotransferase22/20 IU/mL. …

AdultMale0301 basic medicinemedicine.medical_specialtyAdolescentPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseLipid dropletInternal medicineNonalcoholic fatty liver diseasemedicineHumansGenetic Predisposition to DiseaseAlleleChildGeneticsHepatologybiologyMembrane ProteinsAlanine TransaminaseLipaseMiddle AgedHepatologyLipid Metabolismmedicine.diseasedigestive system diseases030104 developmental biologyEndocrinologyHaplotypesLiverAlanine transaminasePatatin-like phospholipaseadolescent; adult; alanine transaminase; case-control studies; child; female; genetic predisposition to disease; haplotypes; humans; lipase; lipid metabolism; liver; male; membrane proteins; middle aged; non-alcoholic fatty liver disease; polymorphism; single nucleotide; hepatologyCase-Control Studiesbiology.proteinFemale030211 gastroenterology & hepatologySteatosisSteatohepatitis
researchProduct

Urea cycle dysregulation in non-alcoholic fatty liver disease.

2018

Background & Aims: In non-alcoholic steatohepatitis (NASH), the function of urea cycle enzymes (UCEs) may be affected, resulting in hyperammonemia and the risk of disease progression. We aimed to determine whether the expression and function of UCEs are altered in an animal model of NASH and in patients with non-alcoholic fatty liver disease (NAFLD), and whether this process is reversible. Methods: Rats were first fed a high-fat, high-cholesterol diet for 10 months to induce NASH, before being switched onto a normal chow diet to recover. In humans, we obtained liver biopsies from 20 patients with steatosis and 15 with NASH. Primary rat hepatocytes were isolated and cultured with free fatty …

AdultMale0301 basic medicinemedicine.medical_specialtyCarbamoyl-Phosphate Synthase (Ammonia)Ornithine transcarbamylase03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAmmoniaGlutamate-Ammonia LigaseNon-alcoholic Fatty Liver DiseaseInternal medicineGene expressionmedicineAnimalsHumansUreaRats WistarPromoter Regions GeneticCells CulturedOrnithine CarbamoyltransferaseAgedHepatologyChemistryFatty liverHyperammonemiaDNA MethylationMiddle Agedmedicine.diseaseRats030104 developmental biologyEndocrinologyLiverUrea cycleHepatocytesUreaFemale030211 gastroenterology & hepatologySteatohepatitisSteatosis
researchProduct

Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis

2018

Hepatic vitamin D receptor (VDR) expression is increased in patients with nonalcoholic fatty liver (NAFL) and is required for liver steatosis in an NAFL mouse model. However, how hepatocyte VDR is involved in setting up steatosis remains unclear. The authors transduced human hepatocyte-derived cells with an adenoviral vector encoding human VDR and found that angiopoietin-like protein 8 (ANGPTL8) expression was increased upon VDR activation by vitamin D or lithocholic acid. The mRNA levels of hepatic VDR- and vitamin D-related genes [cytochrome P450 (CYP) 2R1, CYP27A1, and CYP3A4] were higher in NAFL patients compared with normal liver subjects. Noteworthy, hepatic ANGPTL8 mRNA and protein l…

AdultMale0301 basic medicinemedicine.medical_specialtyLithocholic acidPeptide HormonesFatty Acids NonesterifiedCalcitriol receptorPathology and Forensic Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAngiopoietin-Like Protein 8Non-alcoholic Fatty Liver DiseaseInternal medicineCYP27A1medicineHumansInsulinCells CulturedTriglyceridesGene knockdownCYP3A4Fatty liverMiddle Agedmedicine.diseaseAngiopoietin-like Proteins030104 developmental biologymedicine.anatomical_structureEndocrinologyGene Expression RegulationchemistryCase-Control StudiesHepatocyteHepatocytesReceptors CalcitriolFemale030211 gastroenterology & hepatologySteatosisThe American Journal of Pathology
researchProduct

Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis

2020

Non-alcoholic fatty liver disease (NAFLD) is becoming the main cause of liver disease in Western countries, especially in morbidly obese patients (MOPs). The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recently studied because of its possible involvement in the pathogenesis of NAFLD, but its role, at least in MOPs, is still controversial. The aim of this study was to clarify the correlation between the circulating levels of the PCSK9 protein (cPCSK9) and its hepatic expression with the severity of liver damage in a population of MOPs with NAFLD undergoing bariatric surgery. PCSK9 mRNA was positively correlated with FASN, PPARγ and PPARα mRNAs, while no significant differe…

AdultMale0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaPopulationBariatric SurgeryInflammation030204 cardiovascular system & hematologySeverity of Illness IndexPathogenesisNon-alcoholic fatty liver disease (NAFLD)03 medical and health sciencesBallooning degenerationLiver disease0302 clinical medicineInternal medicinemedicineHumansMorbidly obese patients (MOPs)educationMolecular Biologyeducation.field_of_studybusiness.industryPCSK9Fatty liverCell BiologyMiddle AgedLipid Metabolismmedicine.diseaseObesity MorbidFatty LiverProprotein convertase subtilisin/kexin type 9 (PCSK9)030104 developmental biologyEndocrinologyLiverFemaleProprotein Convertase 9medicine.symptomSteatosisbusiness
researchProduct